Drugs / Aclidinium Bromide/Formoterol Fumarate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01437397 | Sep 2011 → Feb 2013 | chronic obstructive pulmonary disease | AstraZeneca | Completed | Mixed |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-09-07 | AstraZeneca | Results Duaklir significantly improves lung function in COPD patients astrazeneca.com ↗
These results demonstrate the improvement in lung function achieved by the combination of aclidinium and formoterol compared to single LAMA bronchodilators tiotropium and aclidinium, with comparable safety. |
| 2014-11-24 | AstraZeneca | Regulatory Duaklir® Genuair® approved in the European Union for chronic obstructive pulmonary disease astrazeneca.com ↗
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-09-07 | AstraZeneca | Duaklir significantly improves lung function in COPD patients astrazeneca.com ↗ |
| 2014-11-24 | AstraZeneca | Duaklir® Genuair® approved in the European Union for chronic obstructive pulmonary disease astrazeneca.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aclidinium Bromide/Formoterol Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01437397 ↗ |
| Known as | AB/FF | “investigating the efficacy of aclidinium bromide/formoterol fumarate (AB/FF) fixed-dose combination versus monotherapy or placebo” PMID 31827323 ↗ Dec 2019 |
| Route | Inhaled | “Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day” NCT01437397 ↗ |